Header Logo

Connection

Michael Cookson to Male

Back to Details
This is a "connection" page, showing publications Michael Cookson has written about Male.
Michael Cookson
Connection Strength
2.976
Male
  1. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. J Urol. 2021 Jan; 205(1):22-29.
    View in: PubMed
    Score: 0.059
  2. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J Urol. 2021 Jan; 205(1):14-21.
    View in: PubMed
    Score: 0.059
  3. Editorial Comment. J Urol. 2020 05; 203(5):931-932.
    View in: PubMed
    Score: 0.057
  4. The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer. Investig Clin Urol. 2020 02; 61(Suppl 1):S3-S7.
    View in: PubMed
    Score: 0.057
  5. Urology perspective on the expanding world of germline testing for prostate cancer. Can J Urol. 2019 10; 26(5 Suppl 2):5-6.
    View in: PubMed
    Score: 0.055
  6. Recent trends in the management of advanced prostate cancer. F1000Res. 2018; 7.
    View in: PubMed
    Score: 0.052
  7. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. J Urol. 2018 12; 200(6):1264-1272.
    View in: PubMed
    Score: 0.051
  8. Castration-Resistant Prostate Cancer: An Algorithmic Approach. Urol Clin North Am. 2017 Nov; 44(4):647-655.
    View in: PubMed
    Score: 0.049
  9. Advances in the management of castration resistant prostate cancer. BMJ. 2016 Oct 17; 355:i4405.
    View in: PubMed
    Score: 0.045
  10. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015. J Urol. 2016 May; 195(5):1444-1452.
    View in: PubMed
    Score: 0.042
  11. Editorial Comment for Bolton et al. J Endourol. 2015 Jul; 29(7):850.
    View in: PubMed
    Score: 0.041
  12. Castration-resistant prostate cancer: AUA guideline amendment. J Urol. 2015 Feb; 193(2):491-9.
    View in: PubMed
    Score: 0.039
  13. Best evidence regarding the superiority or inferiority of robot-assisted radical prostatectomy. Urol Clin North Am. 2014 Nov; 41(4):493-502.
    View in: PubMed
    Score: 0.039
  14. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. 2015 Jan; 67(1):165-170.
    View in: PubMed
    Score: 0.037
  15. Prostate cancer: Could sensitive PSA assays expedite salvage radiotherapy? Nat Rev Urol. 2014 Jan; 11(1):14-5.
    View in: PubMed
    Score: 0.037
  16. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013 Aug; 190(2):429-38.
    View in: PubMed
    Score: 0.036
  17. Positive surgical margins at radical prostatectomy: much ado about nothing? Urol Oncol. 2013 Apr; 31(3):285-7.
    View in: PubMed
    Score: 0.035
  18. A 57-year-old man with a history of prostatectomy and pelvic irradiation presents with recurrent urinary tract infections, hematuria, and pelvic pain. Urology. 2013 Feb; 81(2):221-5.
    View in: PubMed
    Score: 0.035
  19. Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. Urology. 2012 Sep; 80(3):632-40.
    View in: PubMed
    Score: 0.034
  20. National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer. J Urol. 2012 May; 187(5):1571-6.
    View in: PubMed
    Score: 0.033
  21. Inferior vena cava filter strut perforation discovered during right robotic-assisted laparoscopic partial nephrectomy. Urology. 2012 Apr; 79(4):e49-50.
    View in: PubMed
    Score: 0.032
  22. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol. 2013 Aug; 31(6):871-7.
    View in: PubMed
    Score: 0.032
  23. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol. 2011 Sep; 186(3):829-34.
    View in: PubMed
    Score: 0.031
  24. Complications of pelvic lymph node dissection for prostate cancer. Curr Urol Rep. 2011 Jun; 12(3):203-8.
    View in: PubMed
    Score: 0.031
  25. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol. 2010 Oct; 184(4):1296-300.
    View in: PubMed
    Score: 0.029
  26. Margin control in open radical prostatectomy: what are the real outcomes? Urol Oncol. 2010 Mar-Apr; 28(2):205-9.
    View in: PubMed
    Score: 0.029
  27. Should pelvic lymph node dissection be performed with radical prostatectomy? No. J Urol. 2010 Apr; 183(4):1284-5.
    View in: PubMed
    Score: 0.028
  28. Comparison of transfusion requirements between open and robotic-assisted laparoscopic radical prostatectomy. BJU Int. 2010 Oct; 106(7):1036-40.
    View in: PubMed
    Score: 0.028
  29. Open renal biopsy: comorbidities and complications in a contemporary series. BJU Int. 2010 Jul; 106(1):102-6.
    View in: PubMed
    Score: 0.028
  30. Urinary diversion trends at a high volume, single American tertiary care center. J Urol. 2009 Nov; 182(5):2369-74.
    View in: PubMed
    Score: 0.028
  31. Impact of surgeon and hospital volume on outcomes of radical prostatectomy. Urol Oncol. 2010 May-Jun; 28(3):243-50.
    View in: PubMed
    Score: 0.027
  32. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. BJU Int. 2009 Oct; 104(8):1091-7.
    View in: PubMed
    Score: 0.027
  33. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer. J Urol. 2008 Aug; 180(2):451-9; discussion 460.
    View in: PubMed
    Score: 0.025
  34. Effect of a large prostate gland on open and robotically assisted laparoscopic radical prostatectomy. BJU Int. 2008 May; 101(9):1140-4.
    View in: PubMed
    Score: 0.025
  35. Contemporary open radical cystectomy: analysis of perioperative outcomes. J Urol. 2008 Apr; 179(4):1313-8; discussion 1318.
    View in: PubMed
    Score: 0.025
  36. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J Urol. 2007 Dec; 178(6):2385-9; discussion 2389-90.
    View in: PubMed
    Score: 0.024
  37. Urothelial carcinoma of the bladder metastatic to bone marrow presenting as isolated thrombocytopenia. ScientificWorldJournal. 2007 Jun 12; 7:1000-3.
    View in: PubMed
    Score: 0.024
  38. The evidence-based pathway for peri-operative management of open and robotically assisted laparoscopic radical prostatectomy. BJU Int. 2007 May; 99(5):1103-8.
    View in: PubMed
    Score: 0.023
  39. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007 Feb; 177(2):540-5.
    View in: PubMed
    Score: 0.023
  40. Impact of positive surgical margins after radical prostatectomy. Urology. 2006 Aug; 68(2):249-52.
    View in: PubMed
    Score: 0.022
  41. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 2006 Jun; 97(6):1169-72.
    View in: PubMed
    Score: 0.022
  42. Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am. 2006 May; 33(2):201-10, vii.
    View in: PubMed
    Score: 0.022
  43. Positive influence of robotically assisted laparoscopic prostatectomy on the collaborative-care pathway for open radical prostatectomy. BJU Int. 2006 Mar; 97(3):473-5.
    View in: PubMed
    Score: 0.022
  44. Safely reducing length of stay after open radical retropubic prostatectomy under the guidance of a clinical care pathway. Cancer. 2005 Aug 15; 104(4):747-51.
    View in: PubMed
    Score: 0.021
  45. Performance-enhancing supplement use in patients with testicular cancer. Urology. 2005 Aug; 66(2):242-5.
    View in: PubMed
    Score: 0.021
  46. A pilot randomized clinical trial of a smartphone-based application to support at-home PSA screening and culturally tailored prostate cancer education for African American men: A study protocol. Contemp Clin Trials. 2024 Dec; 147:107737.
    View in: PubMed
    Score: 0.020
  47. Ileal conduit urinary diversion in patients with previous history of abdominal/pelvic irradiation. World J Urol. 2004 Oct; 22(4):272-6.
    View in: PubMed
    Score: 0.020
  48. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
    View in: PubMed
    Score: 0.019
  49. Predicting blood loss and transfusion requirements during radical prostatectomy: the significant negative impact of increasing body mass index. J Urol. 2004 May; 171(5):1861-5.
    View in: PubMed
    Score: 0.019
  50. Increased body mass index predicts increased blood loss during radical cystectomy. J Urol. 2004 Mar; 171(3):1077-9.
    View in: PubMed
    Score: 0.019
  51. Complications of contemporary radical nephrectomy: comparison of open vs. laparoscopic approach. Urol Oncol. 2004 Mar-Apr; 22(2):121-6.
    View in: PubMed
    Score: 0.019
  52. Primary renal carcinoid tumor. J Urol. 2004 Jan; 171(1):338.
    View in: PubMed
    Score: 0.019
  53. Health related quality of life in patients treated with radical cystectomy and urinary diversion for urothelial carcinoma of the bladder: development and validation of a new disease specific questionnaire. J Urol. 2003 Nov; 170(5):1926-30.
    View in: PubMed
    Score: 0.018
  54. Decreasing blood loss in patients treated with radical cystectomy: a prospective randomizes trial using a new stapling device. J Urol. 2003 Mar; 169(3):951-4.
    View in: PubMed
    Score: 0.018
  55. Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J Urol. 2003 Jan; 169(1):101-4.
    View in: PubMed
    Score: 0.017
  56. The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA. Urol Oncol. 2002 Sep-Oct; 7(5):195-8.
    View in: PubMed
    Score: 0.017
  57. Beneficial impact of a clinical care pathway in patients with testicular cancer undergoing retroperitoneal lymph node dissection. J Urol. 2002 Jul; 168(1):87-92.
    View in: PubMed
    Score: 0.017
  58. Health related quality of life assessment after radical cystectomy: comparison of ileal conduit with continent orthotopic neobladder. J Urol. 2002 Jul; 168(1):164-7.
    View in: PubMed
    Score: 0.017
  59. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol. 2002 May; 167(5):2032-5; discussion 2036.
    View in: PubMed
    Score: 0.017
  60. Eosinophilic cystitis presenting as a recurrent symptomatic bladder mass following intravesical mitomycin C therapy. J Urol. 2002 Apr; 167(4):1795.
    View in: PubMed
    Score: 0.016
  61. Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol. 2002 Feb; 167(2 Pt 1):502-5.
    View in: PubMed
    Score: 0.016
  62. Lymphoma presenting as a solitary renal hilar mass. Urology. 2002 Jan; 59(1):134-5.
    View in: PubMed
    Score: 0.016
  63. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
    View in: PubMed
    Score: 0.016
  64. Estimated blood loss and transfusion requirements of radical cystectomy. J Urol. 2001 Dec; 166(6):2151-4.
    View in: PubMed
    Score: 0.016
  65. Intrarectal lidocaine during transrectal prostate biopsy: results of a prospective double-blind randomized trial. J Urol. 2001 Dec; 166(6):2178-80.
    View in: PubMed
    Score: 0.016
  66. Health related quality of life assessment after radical prostatectomy in men with prostate specific antigen only recurrence. J Urol. 2001 Dec; 166(6):2286-90.
    View in: PubMed
    Score: 0.016
  67. Prediction of tumour volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores. BJU Int. 2001 Nov; 88(7):722-6.
    View in: PubMed
    Score: 0.016
  68. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. J Urol. 2022 01; 207(1):70-76.
    View in: PubMed
    Score: 0.016
  69. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World J Urol. 2021 Dec; 39(12):4345-4354.
    View in: PubMed
    Score: 0.016
  70. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001 Aug; 166(2):490-3.
    View in: PubMed
    Score: 0.016
  71. Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen. J Urol. 2001 Feb; 165(2):455-8.
    View in: PubMed
    Score: 0.015
  72. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
    View in: PubMed
    Score: 0.015
  73. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. BJU Int. 2021 07; 128(1):79-87.
    View in: PubMed
    Score: 0.015
  74. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int. 2021 05; 127(5):528-537.
    View in: PubMed
    Score: 0.015
  75. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 08 20; 38(24):2798-2811.
    View in: PubMed
    Score: 0.015
  76. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020 06 04; 382(23):2187-2196.
    View in: PubMed
    Score: 0.015
  77. 8q24 genetic variation and comprehensive haplotypes altering familial risk of prostate cancer. Nat Commun. 2020 03 23; 11(1):1523.
    View in: PubMed
    Score: 0.014
  78. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. Prostate. 2020 05; 80(6):527-544.
    View in: PubMed
    Score: 0.014
  79. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urol Oncol. 2020 07; 38(7):639.e1-639.e9.
    View in: PubMed
    Score: 0.014
  80. Update on transrectal ultrasound-guided needle biopsy of the prostate. Mol Urol. 2000; 4(3):93-7; discussion 99.
    View in: PubMed
    Score: 0.014
  81. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urol Oncol. 2020 01; 38(1):3.e17-3.e27.
    View in: PubMed
    Score: 0.014
  82. Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. J Urol. 2020 03; 203(3):522-529.
    View in: PubMed
    Score: 0.014
  83. Bilateral ureteritis cystica with unilateral ureteropelvic junction obstruction. Tech Urol. 1999 Jun; 5(2):108-12.
    View in: PubMed
    Score: 0.014
  84. Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial. J Urol. 2019 03; 201(3):470-477.
    View in: PubMed
    Score: 0.013
  85. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018 06 23; 391(10139):2525-2536.
    View in: PubMed
    Score: 0.013
  86. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. World J Urol. 2019 Jan; 37(1):165-172.
    View in: PubMed
    Score: 0.013
  87. Transition from androgenic to neurosteroidal action of 5a-androstane-3a, 17ß-diol through the type A ?-aminobutyric acid receptor in prostate cancer progression. J Steroid Biochem Mol Biol. 2018 04; 178:89-98.
    View in: PubMed
    Score: 0.012
  88. Effects of primary care physician density, urologist presence, and insurance status on stage of diagnosis for urologic malignancies. Cancer Epidemiol. 2018 02; 52:10-14.
    View in: PubMed
    Score: 0.012
  89. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997 Jul; 158(1):62-7.
    View in: PubMed
    Score: 0.012
  90. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy. Urology. 1997 Jun; 49(6):887-93.
    View in: PubMed
    Score: 0.012
  91. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Br J Urol. 1997 Mar; 79(3):432-8.
    View in: PubMed
    Score: 0.012
  92. Minimally Invasive Versus Open Approach for Cystectomy: Trends in the Utilization and Demographic or Clinical Predictors Using the National Cancer Database. Urology. 2017 May; 103:99-105.
    View in: PubMed
    Score: 0.012
  93. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol. 1997 Feb; 157(2):559-62.
    View in: PubMed
    Score: 0.012
  94. Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. J Urol. 1997 Feb; 157(2):673-6.
    View in: PubMed
    Score: 0.012
  95. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. Urol Oncol. 2017 05; 35(5):286-293.
    View in: PubMed
    Score: 0.011
  96. A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor. J Urol. 2016 Oct; 196(4):1014-20.
    View in: PubMed
    Score: 0.011
  97. Short term complications from transurethral resection of bladder tumor. Can J Urol. 2016 Apr; 23(2):8198-203.
    View in: PubMed
    Score: 0.011
  98. The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Oncology (Williston Park). 2016 Feb; 30(2):187-95, 199.
    View in: PubMed
    Score: 0.011
  99. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels. J Urol. 1995 Sep; 154(3):1070-3.
    View in: PubMed
    Score: 0.010
  100. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. Am J Pathol. 2015 May; 185(5):1385-95.
    View in: PubMed
    Score: 0.010
  101. Can semen analysis predict the presence of antisperm antibodies in patients with primary infertility? World J Urol. 1995; 13(5):318-22.
    View in: PubMed
    Score: 0.010
  102. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urol Oncol. 2015 Jan; 33(1):21.e11-21.e17.
    View in: PubMed
    Score: 0.010
  103. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb; 67(2):241-9.
    View in: PubMed
    Score: 0.010
  104. Impact of complications and hospital-free days on health related quality of life 1 year after radical cystectomy. J Urol. 2014 Nov; 192(5):1360-4.
    View in: PubMed
    Score: 0.010
  105. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. Urology. 2014 Jun; 83(6):1309-15.
    View in: PubMed
    Score: 0.009
  106. An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility. Am J Hum Genet. 2014 Mar 06; 94(3):395-404.
    View in: PubMed
    Score: 0.009
  107. Hormonal therapy for metastatic prostate cancer: issues of timing and total androgen ablation. South Med J. 1994 Jan; 87(1):1-6.
    View in: PubMed
    Score: 0.009
  108. Racial variation in the quality of surgical care for bladder cancer. Cancer. 2014 Apr 01; 120(7):1018-25.
    View in: PubMed
    Score: 0.009
  109. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology. 2014 Jan; 83(1):75-80.
    View in: PubMed
    Score: 0.009
  110. Blood loss associated with radical cystectomy: a prospective, randomized study comparing Impact LigaSure vs. stapling device. Urol Oncol. 2014 Jan; 32(1):45.e11-5.
    View in: PubMed
    Score: 0.009
  111. Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns. J Urol. 2014 Feb; 191(2):329-34.
    View in: PubMed
    Score: 0.009
  112. Analysis of microsurgical penile revascularization results by etiology of impotence. J Urol. 1993 May; 149(5 Pt 2):1308-12.
    View in: PubMed
    Score: 0.009
  113. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol. 2013 Jun; 189(6):2039-46.
    View in: PubMed
    Score: 0.009
  114. Long-term results with vacuum constriction device. J Urol. 1993 Feb; 149(2):290-4.
    View in: PubMed
    Score: 0.009
  115. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol. 2013 Jun; 63(6):1049-58.
    View in: PubMed
    Score: 0.009
  116. Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? J Urol. 2013 Feb; 189(2):541-7.
    View in: PubMed
    Score: 0.009
  117. Volume outcomes of cystectomy--is it the surgeon or the setting? J Urol. 2012 Dec; 188(6):2139-44.
    View in: PubMed
    Score: 0.009
  118. Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. J Urol. 2013 Feb; 189(2):507-13.
    View in: PubMed
    Score: 0.009
  119. ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. BJU Int. 2012 Dec; 110(11 Pt B):E641-6.
    View in: PubMed
    Score: 0.008
  120. Racial variation in the quality of surgical care for prostate cancer. J Urol. 2012 Oct; 188(4):1279-85.
    View in: PubMed
    Score: 0.008
  121. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan; 63(1):45-57.
    View in: PubMed
    Score: 0.008
  122. Psychometric characteristics of a condition-specific, health-related quality-of-life survey: the FACT-Vanderbilt Cystectomy Index. Urology. 2012 Jul; 80(1):77-83.
    View in: PubMed
    Score: 0.008
  123. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One. 2012; 7(5):e36669.
    View in: PubMed
    Score: 0.008
  124. Recovery of urinary function after radical prostatectomy: identification of trajectory cluster groups. J Urol. 2012 Apr; 187(4):1346-51.
    View in: PubMed
    Score: 0.008
  125. National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol. 2012 Mar; 187(3):816-21.
    View in: PubMed
    Score: 0.008
  126. Spurious elevation of serum PSA after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies. Prostate Cancer Prostatic Dis. 2012 Jun; 15(2):182-8.
    View in: PubMed
    Score: 0.008
  127. Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol. 2011 Dec; 186(6):2221-7.
    View in: PubMed
    Score: 0.008
  128. Tumour size, tumour complexity, and surgical approach are associated with nephrectomy type in small renal cortical tumours treated electively. BJU Int. 2012 Jun; 109(11):1607-13.
    View in: PubMed
    Score: 0.008
  129. Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. BJU Int. 2012 Jan; 109(2):226-32.
    View in: PubMed
    Score: 0.008
  130. Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. Urology. 2011 Jul; 78(1):99-104.
    View in: PubMed
    Score: 0.008
  131. Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. J Urol. 2011 Jun; 185(6):2102-7.
    View in: PubMed
    Score: 0.008
  132. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol. 2011 Jun; 59(6):923-8.
    View in: PubMed
    Score: 0.008
  133. The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Causes Control. 2011 Mar; 22(3):417-26.
    View in: PubMed
    Score: 0.008
  134. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods. World J Urol. 2011 Feb; 29(1):15-20.
    View in: PubMed
    Score: 0.007
  135. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J Urol. 2011 Jan; 185(1):90-6.
    View in: PubMed
    Score: 0.007
  136. Smaller prostate size predicts high grade prostate cancer at final pathology. J Urol. 2010 Sep; 184(3):930-7.
    View in: PubMed
    Score: 0.007
  137. Comparative analysis of whole mount processing and systematic sampling of radical prostatectomy specimens: pathological outcomes and risk of biochemical recurrence. J Urol. 2010 Oct; 184(4):1334-40.
    View in: PubMed
    Score: 0.007
  138. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol. 2010 May; 183(5):1732-7.
    View in: PubMed
    Score: 0.007
  139. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw. 2010 Feb; 8(2):240-62.
    View in: PubMed
    Score: 0.007
  140. Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival. J Urol. 2010 Mar; 183(3):990-6.
    View in: PubMed
    Score: 0.007
  141. Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. J Urol. 2009 Dec; 182(6):2695-701.
    View in: PubMed
    Score: 0.007
  142. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy. J Urol. 2009 Nov; 182(5):2291-5.
    View in: PubMed
    Score: 0.007
  143. Immediate surgical outcomes for radical prostatectomy in the University HealthSystem Consortium Clinical Data Base: the impact of hospital case volume, hospital size and geographical region on 48,000 patients. BJU Int. 2009 Nov; 104(10):1442-5.
    View in: PubMed
    Score: 0.007
  144. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. BJU Int. 2009 Oct; 104(7):934-7.
    View in: PubMed
    Score: 0.007
  145. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J Urol. 2009 May; 181(5):2064-70.
    View in: PubMed
    Score: 0.007
  146. Primary endoscopic management versus open revision of ureteroenteric anastomotic strictures after urinary diversion--single institution contemporary series. J Endourol. 2009 Mar; 23(3):551-5.
    View in: PubMed
    Score: 0.007
  147. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Cancer. 2009 Feb 15; 115(4):770-5.
    View in: PubMed
    Score: 0.007
  148. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol. 2009 Feb; 181(2):540-5; discussion 546.
    View in: PubMed
    Score: 0.007
  149. Prognostic factors in T3b renal cell carcinoma. World J Urol. 2009 Feb; 27(1):75-9.
    View in: PubMed
    Score: 0.007
  150. Waiting time from initial urological consultation to nephrectomy for renal cell carcinoma--does it affect survival? J Urol. 2008 Jun; 179(6):2152-7.
    View in: PubMed
    Score: 0.006
  151. Neovesical-urethral anastomotic stricture after orthotopic urinary diversion: presentation and management. BJU Int. 2008 Jan; 101(2):219-22.
    View in: PubMed
    Score: 0.006
  152. Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men. Prostate Cancer Prostatic Dis. 2008; 11(3):264-9.
    View in: PubMed
    Score: 0.006
  153. Association of procedure volume with radical cystectomy outcomes in a nationwide database. J Urol. 2007 Oct; 178(4 Pt 1):1418-21; discussion 1421-2.
    View in: PubMed
    Score: 0.006
  154. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol. 2007 Aug; 178(2):597-601.
    View in: PubMed
    Score: 0.006
  155. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007 Jun; 177(6):2106-31.
    View in: PubMed
    Score: 0.006
  156. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007 Nov; 28(6):763-9.
    View in: PubMed
    Score: 0.006
  157. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007 Jul; 178(1):68-73; discussion 73.
    View in: PubMed
    Score: 0.006
  158. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May; 177(5):1777-81.
    View in: PubMed
    Score: 0.006
  159. Comparison of length of hospital stay between radical retropubic prostatectomy and robotic assisted laparoscopic prostatectomy. J Urol. 2007 Mar; 177(3):929-31.
    View in: PubMed
    Score: 0.006
  160. Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia. Cancer Causes Control. 2007 May; 18(4):375-84.
    View in: PubMed
    Score: 0.006
  161. Urothelial carcinoma of the prostate. Urology. 2007 Jan; 69(1 Suppl):50-61.
    View in: PubMed
    Score: 0.006
  162. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis. 2007; 10(2):137-42.
    View in: PubMed
    Score: 0.006
  163. Toxicity following high-dose salvage radiotherapy after radical prostatectomy. BJU Int. 2007 Mar; 99(3):529-33.
    View in: PubMed
    Score: 0.006
  164. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer. 2006 Nov 15; 107(10):2361-7.
    View in: PubMed
    Score: 0.006
  165. Sperm banking: use and outcomes in patients treated for testicular cancer. BJU Int. 2007 Jan; 99(1):33-6.
    View in: PubMed
    Score: 0.006
  166. Androgen and anti-androgen treatment modulates androgen receptor activity and DJ-1 stability. Prostate. 2006 Aug 01; 66(11):1177-93.
    View in: PubMed
    Score: 0.006
  167. Patterns of initial transitional cell recurrence in patients after cystectomy. J Urol. 2006 Jun; 175(6):2054-7.
    View in: PubMed
    Score: 0.005
  168. Morbidity and efficacy of genitofemoral nerve grafts with radical retropubic prostatectomy. Urology. 2006 Apr; 67(4):789-92.
    View in: PubMed
    Score: 0.005
  169. Significance of atypical and suspicious small acinar proliferations, and high grade prostatic intraepithelial neoplasia on prostate biopsy: implications for cancer detection and biopsy strategy. J Urol. 2006 Mar; 175(3 Pt 1):929-33; discussion 933.
    View in: PubMed
    Score: 0.005
  170. Robotic assisted laparoscopic radical prostatectomy versus retropubic radical prostatectomy: a prospective assessment of postoperative pain. J Urol. 2005 Sep; 174(3):912-4; discussion 914.
    View in: PubMed
    Score: 0.005
  171. Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes. J Urol. 2005 Jun; 173(6):1897-902.
    View in: PubMed
    Score: 0.005
  172. Urethral recurrence in patients following orthotopic urinary diversion. J Urol. 2004 Oct; 172(4 Pt 1):1338-41.
    View in: PubMed
    Score: 0.005
  173. Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy. J Urol. 2004 Sep; 172(3):882-4.
    View in: PubMed
    Score: 0.005
  174. Complications of inguinal and pelvic lymphadenectomy for squamous cell carcinoma of the penis: a contemporary series. J Urol. 2004 Aug; 172(2):494-7.
    View in: PubMed
    Score: 0.005
  175. Adverse prognostic significance of capsular incision with radical retropubic prostatectomy. J Urol. 2004 Jul; 172(1):119-23.
    View in: PubMed
    Score: 0.005
  176. Benefit of radical cystectomy in the elderly patient with significant co-morbidities. Urol Oncol. 2004 May-Jun; 22(3):178-81.
    View in: PubMed
    Score: 0.005
  177. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol. 2004 Feb; 171(2 Pt 1):646-51.
    View in: PubMed
    Score: 0.005
  178. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol. 2003 Oct; 170(4 Pt 1):1085-7.
    View in: PubMed
    Score: 0.005
  179. Partial nephrectomy safely preserves renal function in patients with a solitary kidney. J Urol. 2003 Jan; 169(1):79-81.
    View in: PubMed
    Score: 0.004
  180. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol. 2003 Jan; 169(1):145-7; discussion 147-8.
    View in: PubMed
    Score: 0.004
  181. Orthotopic neobladder following radical cystectomy in patients with high perioperative risk and co-morbid medical conditions. J Urol. 2002 Dec; 168(6):2454-6.
    View in: PubMed
    Score: 0.004
  182. Causes of increased length of stay following radical cystectomy. Urol Nurs. 2002 Oct; 22(5):319-23, 339.
    View in: PubMed
    Score: 0.004
  183. Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J Urol. 2002 May; 167(5):2012-6.
    View in: PubMed
    Score: 0.004
  184. Routine postoperative intensive care monitoring is not necessary after radical cystectomy. J Urol. 2002 Mar; 167(3):1321-4.
    View in: PubMed
    Score: 0.004
  185. Causes of increased hospital stay after radical cystectomy in a clinical pathway setting. J Urol. 2002 Jan; 167(1):208-11.
    View in: PubMed
    Score: 0.004
  186. Radical cystectomy is safe in elderly patients at high risk. J Urol. 2001 Sep; 166(3):938-41.
    View in: PubMed
    Score: 0.004
  187. Clinical and pathologic findings in hereditary spastic paraparesis with spastin mutation. Neurology. 2000 Jul 12; 55(1):89-94.
    View in: PubMed
    Score: 0.004
  188. [Incidence and clinical significance of false-negative sextant biopsies of the prostate]. Urologe A. 1998 Nov; 37(6):660.
    View in: PubMed
    Score: 0.003
  189. Repeat transrectal ultrasound-guided prostate biopsy: a strategy to improve the reliability of needle biopsy grading in patients with well-differentiated prostate cancer. Urology. 1998 Oct; 52(4):659-62.
    View in: PubMed
    Score: 0.003
  190. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol. 1998 Apr; 159(4):1247-50.
    View in: PubMed
    Score: 0.003
  191. Radical cystectomy in the octogenarian. J Urol. 1997 Dec; 158(6):2113-7.
    View in: PubMed
    Score: 0.003
  192. Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology. 1997 Mar; 49(3A Suppl):113-8.
    View in: PubMed
    Score: 0.003
  193. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology. 1997 Mar; 49(3A Suppl):46-55.
    View in: PubMed
    Score: 0.003
  194. Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Urology. 1997 Mar; 49(3A Suppl):95-101.
    View in: PubMed
    Score: 0.003
  195. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol. 1996 Oct; 156(4):1286-7.
    View in: PubMed
    Score: 0.003
  196. A prospective evaluation of leak point pressure, bladder compliance and clinical status in myelodysplasia patients with tethered spinal cords. J Urol. 1994 Jan; 151(1):177-80; discussion 180-1.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.